Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Prostate Cell News
Prostate Cell News is an online resource summarizing the latest prostate cell research.
Subscribe|Follow Us On
Programmable mRNA 3′UTR Engineering Restores MHC-I and Overcomes Immune Evasion in Prostate Cancer
[Nature Biomedical Engineering] Scientists developed a programmable RNA engineering platform, termed the 3′UTR CRISPR/dCas13 Engineering System, to precisely manipulate mRNA alternative polyadenylation in vivo.
UCLA Researchers Awarded $1.7 Million Department of Defense Grant to Advance Next-Generation CAR T-Cell Therapies for Prostate Cancer
[UCLA Health] Researchers from the UCLA Health Jonsson Comprehensive Cancer Center have received a $1.7 million grant from the US Department of Defense’s Congressionally Directed Medical Research Programs to develop new strategies to improve CAR T-cell therapies for metastatic CRPC.
Identification of Targets of Clinical FOXA1 Mutants Involved in EMT and Immune Suppression in Prostate Cancer
[Communications Biology] Scientists provide distinct insight into how FOXA1 forkhead DNA-binding domain (FKHD) mutations drive prostate cancer progression and highlight potential therapeutic targets in tumors.
Mechanisms of Resistance to Androgen Deprivation Therapy in Prostate Cancer
[Molecular Aspects of Medicine] The authors summarize the key molecular drivers of prostate cancer resistance and evaluates emerging invasive biomarkers with potential clinical utility.
The Glycobiology of Prostate Cancer: An Update
[Oncogene] Scientists discuss the role of glycans in fundamental mechanisms controlling prostate cancer growth, metastasis, and immune evasion.
MicroRNA-6833-3p Drives Prostate Cancer Progression and Stemness by Targeting the NUMB-Mediated NOTCH Signaling Pathway
[Cell Cycle] Scientists revealed that miR-6833-3p drives prostate carcinogenesis and enhances tumor-initiating cell properties through suppression of the NUMB-mediated NOTCH signaling axis
ERG Orchestrates a Dedifferentiation-Senescence-Inflammation Triad in Prostate Cancer
[Molecular Cancer Research] Investigators uncovered a previously unrecognized triad of ERG-driven processes –dedifferentiation, senescence, and inflammation– that may underpin its oncogenic potential and shape prostate cancer initiation and therapeutic response.
Recurrent Intra-Tumor Heterogeneity Is a Hallmark of Metastatic Prostate Cancer
[Nature Communications] To define mechanisms underpinning metastatic heterogeneity in late-stage disease, scientists employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions obtained from patients through rapid autopsy.
Targeting Oncogenic TβRI Signaling Inhibits Androgen-Independent Prostate Cancer Growth and Metastasis
[Signal Transduction and Targeted Therapy] In a preclinical human orthotopic metastatic CRPC mouse model, treatment with therapeutic monoclonal antibodies effectively prevented the nuclear accumulation of TβRI-ICD, inhibited epithelial-to-mesenchymal transition, and suppressed tumor growth, invasion, and metastasis.
RadioMedix Announces Receiving FDA Approval of Its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate Cancer
[RadioMedix, Inc.] RadioMedix, Inc. announced that the US FDA has approved Ga 68 PSMA-11, a prostate-specific membrane antigen (PSMA)-targeted diagnostic radiopharmaceutical for positron emission tomography imaging in patients with prostate cancer.
CPRIT Invests Over $11 Million to Fuel UH Breakthroughs in Cancer Research
[University of Houston] With $250,000 in Cancer Prevention and Research Institute of Texas (CPRIT) funding, Dr. Qin Feng, associate professor of biology and biochemistry, is working to stop the progression of prostate cancer. Her research goal is to provide a new treatment option for prostate cancer patients, especially those resistant to current therapies.
MCCC2 Stabilizes LTBP1 via Suppressing SMURF1-Dependent Ubiquitination to Drive Bone Metastasis in Prostate Cancer
[Oncogene] Liquid chromatography-mass spectrometry identified LTBP1 as a direct interacting partner of methylcrotonyl-CoA carboxylase subunit 2 (MCCC2). Functional studies demonstrated that MCCC2 promotes prostate cancer cell migration, invasion in vitro, and bone metastasis in vivo.
Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.
